C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.010
+0.020 (0.67%)
At close: Feb 21, 2025, 4:00 PM
3.000
-0.010 (-0.33%)
After-hours: Feb 21, 2025, 4:45 PM EST
C4 Therapeutics Employees
C4 Therapeutics had 145 employees as of December 31, 2023. The number of employees decreased by 1 or -0.68% compared to the previous year.
Employees
145
Change (1Y)
-1
Growth (1Y)
-0.68%
Revenue / Employee
$232,193
Profits / Employee
-$727,566
Market Cap
212.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | 99 | 11 | 12.50% |
| Dec 31, 2019 | 88 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CCCC News
- 2 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire
- 3 months ago - C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewsWire
- 4 months ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - GlobeNewsWire
- 4 months ago - C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - GlobeNewsWire
- 5 months ago - C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 5 months ago - C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 6 months ago - C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors - GlobeNewsWire